Premium
RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY
Author(s) -
DelfauLarue M.H.,
Boulland M.L.,
Feugier P.,
Maisonneuve H.,
Casasnovas O.,
Haioun C.,
Pica G.M.,
Lamy de la Chapelle T.,
Ysebaert L.,
Tilly H.,
Eisenmann J.C.,
Le Gouil S.,
Ribrag V.,
Jardel H.,
Glaisner S.,
Cartron G.,
Salles G.,
Xerri L.,
Fest T.,
Morschhauser F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.77_2629
Subject(s) - medicine , follicular lymphoma , rituximab , oncology , minimal residual disease , lenalidomide , fludarabine , regimen , gastroenterology , surrogate endpoint , lymphoma , progression free survival , surgery , bone marrow , chemotherapy , cyclophosphamide , multiple myeloma